Skip to content

Time Restricted Feeding for Weight Loss and Cardio-protection

Time Restricted Feeding for Weight Loss and Cardio-protection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02948517
Enrollment
31
Registered
2016-10-28
Start date
2016-09-30
Completion date
2017-08-31
Last updated
2018-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease, Weight Loss

Brief summary

Time restricted feeding (TRF) is a novel form of intermittent fasting that involves confining the period of food intake to 8 h/d (e.g. 10 am to 6 pm) without calorie counting. TRF is effective for weight loss and cardio-protection in obese adults. It is of great interest to see whether subjects can adhere to TRF for longer periods of time, and to see what degree of weight loss that can be achieved with TRF. Accordingly, the aims of this trial are: Aim 1: To determine if TRF can be implemented to facilitate weight loss in obese adults, and Aim 2: To determine if TRF can produce clinically meaningful reductions in plasma lipids, blood pressure, insulin resistance, and inflammatory markers.

Detailed description

Time restricted feeding (TRF) is a novel form of intermittent fasting that involves confining the period of food intake to 8 h/d (e.g. 10 am to 6 pm) without calorie counting. Recent findings from short-term uncontrolled trials suggest that TRF is effective for weight loss and cardio-protection in obese adults. In view of these pilot findings, it is of great interest to see whether subjects can adhere to TRF for longer periods of time, and to see what degree of weight loss that can be achieved with TRF. Accordingly, the aims of this trial are: Aim 1: To determine if TRF can be implemented to facilitate weight loss in obese adults, and Aim 2: To determine if TRF can produce clinically meaningful reductions in plasma lipids, blood pressure, insulin resistance, and inflammatory markers. To test the study objectives, a 14-week randomized, controlled, parallel-arm trial, divided into 2 consecutive periods: (1) 2-week baseline; and (2) 12-week weight loss, will be implemented. Obese subjects (n = 40) will be randomized to 1 of 2 groups: (1) TRF (n = 20), or (2) control (n = 20). This study will be the first randomized controlled trial of TRF, and will show that TRF can be implemented to help obese individuals lose weight and lower risk of coronary heart disease.

Interventions

OTHERTime restricted feeding

Time restricted feeding

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female * Body mass index (BMI) between 30.0 and 40 kg/m2 * Age between 25 and 65 years * Sedentary (light exercise less than 1 h per week) or moderately active (moderate exercise 1 to 2 h per week) * Weight stable for \>3 months prior to the beginning of the study (gain or loss \<4 kg) * Able to give written informed consent

Exclusion criteria

* Smoker * Diabetic * History of cardiovascular disease (myocardial infarction or stroke) * Taking weight loss medications * History of eating disorders * Night-shift workers * Perimenopausal * Pregnant or trying to become pregnant

Design outcomes

Primary

MeasureTime frame
Body weight12 weeks

Secondary

MeasureTime frame
Plasma lipids12 weeks
Blood pressure12 weeks
Insulin resistance measured by Homeostatic model assessment (HOMA)12 weeks
Inflammatory markers: Tumor necrosis factor-alpha (TNF) and Interleukin-6 (IL-6)12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026